|
1
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Disease Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cho E, Adami HO and Lindblad P:
Epidemiology of renal cell cancer. Hematol Oncol Clin North Am.
25:651–665. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Makhov P, Joshi S, Ghatalia P, Kutikov A,
Uzzo RG and Kolenko VM: Resistance to systemic therapies in clear
cell renal cell carcinoma: Mechanisms and management strategies.
Mol Cancer Ther. 17:1355–1364. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tippu Z, Au L and Turajlic S: Evolution of
renal cell carcinoma. Eur Urol Focus S2405-S4569. 30383–30389.
2020.
|
|
7
|
Mennitto A, Verzoni E, Grassi P, Ratta R,
Fucà G and Procopio G: Multimodal treatment of advanced renal
cancer in 2017. Expert Rev Clin Pharmacol. 10:1395–1402. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eckert D, Buhl S, Weber S, Jäger R and
Schorle H: The AP-2 family of transcription factors. Genome Biol.
6:2462005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lüscher B, Mitchell PJ, Williams T and
Tjian R: Regulation of transcription factor AP-2 by the morphogen
retinoic acid and by second messengers. Genes Dev. 3:1507–1517.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zeng YX, Somasundaram K and el-Deiry WS:
AP2 inhibits cancer cell growth and activates p21WAF1/CIP1
expression. Nat Genet. 15:78–82. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Auman HJ, Nottoli T, Lakiza O, Winger Q,
Donaldson S and Williams T: Transcription factor AP-2gamma is
essential in the extra-embryonic lineages for early
postimplantation development. Development. 129:2733–2747.
2002.PubMed/NCBI
|
|
12
|
Moser M, Pscherer A, Roth C, Becker J,
Mücher G, Zerres K, Dixkens C, Weis J, Guay-Woodford L, Buettner R
and Fässler R: Enhanced apoptotic cell death of renal epithelial
cells in mice lacking transcription factor AP-2beta. Genes Dev.
11:1938–1948. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu L, Shi K, Wang J, Chen W, Shi D, Tian
Y, Guo W, Yu W, Xiao X, Kang T, et al: TFAP2B overexpression
contributes to tumor growth and a poor prognosis of human lung
adenocarcinoma through modulation of ERK and VEGF/PEDF signaling.
Mol Cancer. 13:892014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Konta T, Ichikawa K, Suzuki K, Kudo K,
Satoh H, Kamei K, Nishidate E and Kubota I: A microarray analysis
of urinary microRNAs in renal diseases. Clin Exp Nephrol.
18:711–717. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wong NW, Chen Y, Chen S and Wang X:
OncomiR: An online resource for exploring pan-cancer microRNA
dysregulation. Bioinformatics. 34:713–715. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu S, Xiao Z, Ai F, Liu F, Chen X, Cao K,
Ren W, Zhang X, Shu P and Zhang D: miR-142-5p promotes development
of colorectal cancer through targeting SDHB and facilitating
generation of aerobic glycolysis. Biomed Pharmacother.
92:1119–1127. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Z, Liu Z, Fang X and Yang H:
MiR-142-5p suppresses tumorigenesis by targeting PIK3CA in
non-small cell lung cancer. Cell Physiol Biochem. 43:2505–2515.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheng D, Li J, Zhang L and Hu L:
miR-142-5p suppresses proliferation and promotes apoptosis of human
osteosarcoma cell line, HOS, by targeting PLA2G16 through the
ERK1/2 signaling pathway. Oncol Lett. 17:1363–1371. 2019.PubMed/NCBI
|
|
20
|
Liu L, Liu S, Duan Q, Chen L, Wu T, Qian
H, Yang S, Xin D, He Z and Guo Y: MicroRNA-142-5p promotes cell
growth and migration in renal cell carcinoma by targeting BTG3. Am
J Transl Res. 9:2394–2402. 2017.PubMed/NCBI
|
|
21
|
Oya M, Mikami S, Mizuno R, Miyajima A,
Horiguchi Y, Nakashima J, Marumo K, Mukai M and Murai M:
Differential expression of activator protein-2 isoforms in renal
cell carcinoma. Urology. 64:162–167. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tun HW, Marlow LA, von Roemeling CA,
Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ and
Copland JA: Pathway signature and cellular differentiation in clear
cell renal cell carcinoma. PLoS One. 5:e106962010. View Article : Google Scholar : PubMed/NCBI
|
